B-cell NHL: phase 1/2 results with fenretinide + rituximab

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Takeaway

  • In patients with B-cell non-Hodgkin lymphoma (B-NHL), fenretinide + rituximab (Rituxan) delivered moderate, but durable response with encouraging tolerability.

Why this matters

  • Fenretinide has demonstrated anti-tumor action in preclinical studies.

Study design

  • Phase 1/2 ...